Tuesday, December 7, 2021

Chemoimmunotherapy dramatically improved survival of high-risk neuroblastoma patients

A recent phase II clinical trial results suggest that the monoclonal antibody hu14.18K322A could help change treatment of children with high-risk neuroblastoma.

from Top Health News -- ScienceDaily https://ift.tt/3Is7pm2
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Only 13 % know: The one-minute self-exam that could save young men’s lives

A new survey shows most Americans wrongly think testicular cancer is an older man's issue, despite it most commonly affecting men aged 2...